Identification

Name
Chlorzoxazone
Accession Number
DB00356  (APRD00308)
Type
Small Molecule
Groups
Approved
Description

A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)

Structure
Thumb
Synonyms
  • 2-hydroxy-5-chlorobenzoxazole
  • 5-chloro-2-Benzoxazolinone
  • 5-chloro-2-Benzoxazolol
  • 5-chloro-2-Benzoxazolone
  • 5-chloro-2-Hydroxybenzoxazole
  • 5-chloro-2(3H)-benzoxazolone
  • 5-chloro-3H-benzooxazol-2-one
  • 5-Chlorobenzoxazolidone
  • 5-chlorobenzoxazolin-2-one
  • Chlorzoxane
  • Chlorzoxazon
  • Chlorzoxazona
  • Chlorzoxazone
  • Chlorzoxazonum
  • Clorzoxazona
  • Clorzoxazone
External IDs
MI 315 / USAF MA-10
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Parafon Forte DSCTablet500 mg/1OralJanssen Pharmaceuticals1987-06-152017-11-01Us
Parafon Forte DSCTablet500 mg/1OralRemedy Repack2012-11-282017-11-07Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ChlorzoxazoneTablet500 mg/1OralAidarex Pharmaceuticals LLC2011-08-22Not applicableUs
ChlorzoxazoneTablet500 mg/1OralClinical Solutions Wholsesale2011-08-222017-06-29Us00591 2520 01 nlmimage10 b73a5bf2
ChlorzoxazoneTablet500 mg/1OralA S Medication Solutions2011-08-22Not applicableUs
ChlorzoxazoneTablet500 mg/1Oralbryant ranch prepack2008-12-232017-07-20Us
ChlorzoxazoneTablet500 mg/1OralRebel Distributors1988-05-04Not applicableUs
ChlorzoxazoneTablet500 mg/1OralA S Medication Solutions2011-08-222017-06-20Us
ChlorzoxazoneTablet500 mg/1OralA S Medication Solutions2011-08-22Not applicableUs
ChlorzoxazoneTablet375 mg/1OralMikart, Inc.2010-06-01Not applicableUs
ChlorzoxazoneTablet500 mg/1OralNucare Pharmaceuticals, Inc.2011-08-22Not applicableUs
ChlorzoxazoneTablet500 mg/1OralDispensing Solutions, Inc.2011-01-16Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ChlorzoxazoneTablet500 mg/1OralRemedy Repack2017-11-15Not applicableUs
International/Other Brands
Myoflexin (Zentiva) / Paraflex (BioPhausia) / Relaxazone / Remular / Remular-S / Solaxin (Eisai) / Strifon Forte DSC
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acetazone ForteChlorzoxazone (250 mg) + Acetaminophen (300 mg)TabletOralTeva1991-12-31Not applicableCanada
Acetazone Forte C8Chlorzoxazone (250 mg) + Acetaminophen (300 mg) + Codeine phosphate (8 mg)TabletOralTeva1991-12-31Not applicableCanada
Back-aid Forte - TabChlorzoxazone (250 mg) + Acetaminophen (300 mg)TabletOralRougier Pharma Division Of Ratiopharm Inc1995-12-312015-10-01Canada
Extra Strength Tylenol Aches and StrainsChlorzoxazone (250 mg) + Acetaminophen (500 mg)TabletOralMcneil Consumer Healthcare Division Of Johnson & Johnson Inc1996-12-312008-08-07Canada
Gin Pain Pills - TabChlorzoxazone (250 mg) + Acetaminophen (300 mg)TabletOralStella Pharmaceutical Canada Inc.1996-09-052002-07-05Canada
Parafon ForteChlorzoxazone (250 mg) + Acetaminophen (300 mg)TabletOralMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1949-12-311999-08-12Canada
Parafon Forte C8 W Codeine TabChlorzoxazone (250 mg) + Acetaminophen (300 mg) + Codeine phosphate (8 mg)TabletOralMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1985-12-311999-11-09Canada
Parafon Forte TabletsChlorzoxazone (250 mg) + Acetaminophen (300 mg)TabletOralJohnson & Johnson Merck Consumer Pharmaceuticals Of Canada1997-07-312008-08-07Canada
Categories
UNII
H0DE420U8G
CAS number
95-25-0
Weight
Average: 169.565
Monoisotopic: 168.993056084
Chemical Formula
C7H4ClNO2
InChI Key
TZFWDZFKRBELIQ-UHFFFAOYSA-N
InChI
InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
IUPAC Name
5-chloro-2,3-dihydro-1,3-benzoxazol-2-one
SMILES
ClC1=CC2=C(OC(=O)N2)C=C1

Pharmacology

Indication

For the relief of discomfort associated with acute painful musculoskeletal conditions.

Structured Indications
Pharmacodynamics

Chlorzoxazone, a synthetic compound, inhibits antigen-induced bronchospasms and, hence, is used to treat asthma and allergic rhinitis. Chlorzoxazone is used as an ophthalmic solution to treat conjunctivitis and is taken orally to treat systemic mastocytosis and ulcerative colitis. Chlorzoxazone is also a centrally-acting agent for painful musculoskeletal conditions. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex a.c. involved in producing and maintaining skeletal muscle spasm of varied etiology. The clinical result is a reduction of the skeletal muscle spasm with relief of pain and increased mobility of the involved muscles.

Mechanism of action

Chlorzoxazone inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Chlorzoxazone also may reduce the release of inflammatory leukotrienes. Chlorzoxazone may act by inhibiting calcium and potassium influx which would lead to neuronal inhibition and muscle relaxation. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm

TargetActionsOrganism
ACalcium-activated potassium channel subunit alpha-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

13-18%

Metabolism

Chlorzoxazone is rapidly metabolized in the liver and is excreted in the urine, primarily in a conjugated form as the glucuronide.

Route of elimination

Chlorzoxazone is rapidly metabolized and is excreted in the urine, primarily in a conjugated form as the glucuronide.

Half life
Not Available
Clearance
Not Available
Toxicity

Oral, mouse: LD50 = 440 mg/kg; Oral, rat: LD50 = 763 mg/kg; Symptoms of overdose include diarrhea, dizziness, drowsiness, headache, light-headedness, nausea, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Chlorzoxazone.Experimental
AbirateroneThe serum concentration of Chlorzoxazone can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Chlorzoxazone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Chlorzoxazone.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Chlorzoxazone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Chlorzoxazone.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Chlorzoxazone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorzoxazone.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Chlorzoxazone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorzoxazone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Chlorzoxazone.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorzoxazone.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Chlorzoxazone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Chlorzoxazone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorzoxazone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chlorzoxazone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Chlorzoxazone.Experimental
AprepitantThe serum concentration of Chlorzoxazone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorzoxazone.Approved, Investigational
ArtemetherThe metabolism of Chlorzoxazone can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Chlorzoxazone.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Chlorzoxazone.Approved
AtazanavirThe metabolism of Chlorzoxazone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Chlorzoxazone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Chlorzoxazone.Investigational, Vet Approved
AzelastineChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Chlorzoxazone can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Chlorzoxazone.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Chlorzoxazone.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Chlorzoxazone.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chlorzoxazone.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Chlorzoxazone.Approved
BetaxololThe metabolism of Chlorzoxazone can be decreased when combined with Betaxolol.Approved
BoceprevirThe metabolism of Chlorzoxazone can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Chlorzoxazone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Chlorzoxazone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chlorzoxazone.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Chlorzoxazone.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Chlorzoxazone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Chlorzoxazone.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Chlorzoxazone.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorzoxazone.Approved, Investigational
BuprenorphineChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Chlorzoxazone can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorzoxazone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorzoxazone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Chlorzoxazone.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Chlorzoxazone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Chlorzoxazone.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Chlorzoxazone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorzoxazone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorzoxazone.Approved
CaffeineThe metabolism of Chlorzoxazone can be decreased when combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Chlorzoxazone.Investigational
CarbamazepineThe metabolism of Chlorzoxazone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorzoxazone.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Carisoprodol.Approved
CelecoxibThe metabolism of Chlorzoxazone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Chlorzoxazone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Chlorzoxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Chlorzoxazone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Chlorzoxazone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorzoxazone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Chlorzoxazone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorzoxazone.Approved
ChloroquineThe metabolism of Chlorzoxazone can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Chlorphenamine.Approved
ChlorpromazineThe metabolism of Chlorzoxazone can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chlorzoxazone.Approved, Investigational, Withdrawn
CholecalciferolThe metabolism of Chlorzoxazone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Chlorzoxazone can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Chlorzoxazone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorzoxazone.Approved, Vet Approved
CitalopramThe metabolism of Chlorzoxazone can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Chlorzoxazone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Chlorzoxazone can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clidinium.Approved
ClobazamThe metabolism of Chlorzoxazone can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Chlorzoxazone.Investigational
ClomipramineThe metabolism of Chlorzoxazone can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Chlorzoxazone.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorzoxazone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Chlorzoxazone.Experimental
ClotrimazoleThe metabolism of Chlorzoxazone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Chlorzoxazone can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Chlorzoxazone can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Chlorzoxazone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorzoxazone.Approved, Illicit
ConivaptanThe serum concentration of Chlorzoxazone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Chlorzoxazone can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorzoxazone.Approved
CyclosporineThe metabolism of Chlorzoxazone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Chlorzoxazone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Chlorzoxazone can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorzoxazone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Chlorzoxazone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Chlorzoxazone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Chlorzoxazone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Chlorzoxazone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Chlorzoxazone can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Chlorzoxazone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorzoxazone.Approved
DesipramineThe metabolism of Chlorzoxazone can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Chlorzoxazone.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorzoxazone.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorzoxazone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorzoxazone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorzoxazone.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Chlorzoxazone.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Chlorzoxazone.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorzoxazone.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Chlorzoxazone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Chlorzoxazone.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Chlorzoxazone.Experimental
DihydroergotamineThe metabolism of Chlorzoxazone can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorzoxazone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorzoxazone.Experimental, Illicit
DiltiazemThe metabolism of Chlorzoxazone can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Chlorzoxazone can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorzoxazone.Approved, Illicit
DisulfiramThe metabolism of Chlorzoxazone can be decreased when combined with Disulfiram.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Chlorzoxazone.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Chlorzoxazone.Vet Approved
DosulepinThe metabolism of Chlorzoxazone can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Doxepin.Approved
DoxycyclineThe metabolism of Chlorzoxazone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorzoxazone.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved, Illicit
DronedaroneThe metabolism of Chlorzoxazone can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Chlorzoxazone.Experimental, Illicit
DuloxetineThe metabolism of Chlorzoxazone can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorzoxazone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Chlorzoxazone.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Chlorzoxazone.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Chlorzoxazone can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Chlorzoxazone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Chlorzoxazone.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Chlorzoxazone can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorzoxazone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Chlorzoxazone.Approved
ErythromycinThe metabolism of Chlorzoxazone can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Chlorzoxazone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorzoxazone.Approved
EthanolChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorzoxazone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Chlorzoxazone.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Chlorzoxazone.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Chlorzoxazone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorzoxazone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Chlorzoxazone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Chlorzoxazone.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Chlorzoxazone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorzoxazone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorzoxazone.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Chlorzoxazone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorzoxazone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Chlorzoxazone.Experimental
FluconazoleThe metabolism of Chlorzoxazone can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Chlorzoxazone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Chlorzoxazone.Approved, Illicit
FluoxetineThe metabolism of Chlorzoxazone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorzoxazone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorzoxazone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorzoxazone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Chlorzoxazone.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Chlorzoxazone.Approved
FluvoxamineThe metabolism of Chlorzoxazone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Chlorzoxazone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Chlorzoxazone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Chlorzoxazone can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Chlorzoxazone.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Chlorzoxazone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorzoxazone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Chlorzoxazone.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Chlorzoxazone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Chlorzoxazone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Chlorzoxazone.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Chlorzoxazone can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorzoxazone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Chlorzoxazone.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Chlorzoxazone.Approved
HydrocodoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorzoxazone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
IdelalisibThe serum concentration of Chlorzoxazone can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Iloperidone.Approved
ImatinibThe metabolism of Chlorzoxazone can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Chlorzoxazone can be decreased when combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Chlorzoxazone can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Chlorzoxazone.Investigational
IsavuconazoniumThe metabolism of Chlorzoxazone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Chlorzoxazone.Approved, Vet Approved
IsoniazidThe metabolism of Chlorzoxazone can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Chlorzoxazone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Chlorzoxazone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Chlorzoxazone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorzoxazone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorzoxazone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorzoxazone.Approved, Investigational
KetoconazoleThe metabolism of Chlorzoxazone can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chlorzoxazone.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorzoxazone.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorzoxazone.Approved
LidocaineThe metabolism of Chlorzoxazone can be decreased when combined with Lidocaine.Approved, Vet Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Chlorzoxazone.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Chlorzoxazone.Approved
LobeglitazoneThe metabolism of Chlorzoxazone can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorzoxazone.Illicit
LopinavirThe metabolism of Chlorzoxazone can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Chlorzoxazone.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorzoxazone.Approved
LorcaserinThe metabolism of Chlorzoxazone can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Chlorzoxazone.Approved
LovastatinThe metabolism of Chlorzoxazone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorzoxazone.Approved
LuliconazoleThe serum concentration of Chlorzoxazone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Chlorzoxazone can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Chlorzoxazone can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorzoxazone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Chlorzoxazone.Illicit, Investigational, Withdrawn
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved, Vet Approved
ManidipineThe metabolism of Chlorzoxazone can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Chlorzoxazone.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Chlorzoxazone.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Chlorzoxazone.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Chlorzoxazone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Chlorzoxazone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorzoxazone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorzoxazone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Chlorzoxazone.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorzoxazone.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Chlorzoxazone.Experimental
MethadoneThe metabolism of Chlorzoxazone can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorzoxazone.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Chlorzoxazone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Chlorzoxazone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorzoxazone.Approved
MethotrimeprazineChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorzoxazone.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Chlorzoxazone.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Chlorzoxazone.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorzoxazone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Chlorzoxazone.Approved
MetoprololThe metabolism of Chlorzoxazone can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineChlorzoxazone may increase the sedative activities of Metyrosine.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Chlorzoxazone.Experimental
MexiletineThe metabolism of Chlorzoxazone can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorzoxazone.Approved, Illicit
MidostaurinThe metabolism of Chlorzoxazone can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved, Investigational
MirabegronThe metabolism of Chlorzoxazone can be decreased when combined with Mirabegron.Approved
MirtazapineChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Chlorzoxazone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorzoxazone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorzoxazone.Approved
NefazodoneThe metabolism of Chlorzoxazone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Chlorzoxazone can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Chlorzoxazone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Chlorzoxazone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Chlorzoxazone can be decreased when combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Chlorzoxazone.Approved, Investigational
NicotineThe metabolism of Chlorzoxazone can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Chlorzoxazone can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chlorzoxazone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Chlorzoxazone.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Chlorzoxazone.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Chlorzoxazone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorzoxazone.Approved, Investigational
OlaparibThe metabolism of Chlorzoxazone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorzoxazone.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Chlorzoxazone.Approved, Illicit
OrphenadrineChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Chlorzoxazone.Investigational
OsimertinibThe serum concentration of Chlorzoxazone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorzoxazone.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Chlorzoxazone.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Chlorzoxazone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chlorzoxazone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorzoxazone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorzoxazone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Chlorzoxazone can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chlorzoxazone.Approved
PanobinostatThe serum concentration of Chlorzoxazone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Chlorzoxazone can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Chlorzoxazone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Chlorzoxazone.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorzoxazone.Approved, Vet Approved
PentobarbitalThe metabolism of Chlorzoxazone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Chlorzoxazone.Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Chlorzoxazone.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Chlorzoxazone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorzoxazone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorzoxazone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Chlorzoxazone.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Chlorzoxazone.Experimental
PhenobarbitalThe metabolism of Chlorzoxazone can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Chlorzoxazone.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Chlorzoxazone.Approved
PhenytoinThe metabolism of Chlorzoxazone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorzoxazone.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorzoxazone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Chlorzoxazone.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Chlorzoxazone.Approved
PizotifenThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Chlorzoxazone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleChlorzoxazone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Chlorzoxazone.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Chlorzoxazone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Chlorzoxazone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorzoxazone.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Chlorzoxazone.Approved
PrimidoneThe metabolism of Chlorzoxazone can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Chlorzoxazone.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorzoxazone.Approved, Vet Approved
PromazineThe metabolism of Chlorzoxazone can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Chlorzoxazone.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlorzoxazone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorzoxazone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Chlorzoxazone.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorzoxazone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Chlorzoxazone.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Chlorzoxazone.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Chlorzoxazone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorzoxazone.Approved
QuinidineThe metabolism of Chlorzoxazone can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Chlorzoxazone can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Chlorzoxazone.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Chlorzoxazone.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Chlorzoxazone can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorzoxazone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorzoxazone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorzoxazone.Approved, Investigational
RifabutinThe metabolism of Chlorzoxazone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Chlorzoxazone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Chlorzoxazone can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorzoxazone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Chlorzoxazone.Investigational
RitonavirThe metabolism of Chlorzoxazone can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Chlorzoxazone can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Chlorzoxazone.Vet Approved
RopiniroleChlorzoxazone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorzoxazone.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Chlorzoxazone.Approved
RotigotineChlorzoxazone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorzoxazone.Approved
SaquinavirThe metabolism of Chlorzoxazone can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorzoxazone.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Chlorzoxazone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Chlorzoxazone.Approved, Investigational, Withdrawn
SertralineThe metabolism of Chlorzoxazone can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorzoxazone.Approved, Vet Approved
SildenafilThe metabolism of Chlorzoxazone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Chlorzoxazone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Chlorzoxazone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Chlorzoxazone.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
St. John's WortThe serum concentration of Chlorzoxazone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Chlorzoxazone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorzoxazone.Approved, Investigational
SulfisoxazoleThe metabolism of Chlorzoxazone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chlorzoxazone.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Chlorzoxazone.Experimental
SuvorexantChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Chlorzoxazone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Chlorzoxazone can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Chlorzoxazone can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorzoxazone.Approved
Tenofovir disoproxilThe metabolism of Chlorzoxazone can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Chlorzoxazone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Chlorzoxazone.Experimental
TeriflunomideThe serum concentration of Chlorzoxazone can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Chlorzoxazone.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Chlorzoxazone.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Chlorzoxazone.Investigational
ThalidomideChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Chlorzoxazone can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorzoxazone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorzoxazone.Approved, Vet Approved
ThioridazineThe metabolism of Chlorzoxazone can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorzoxazone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Chlorzoxazone.Approved, Investigational
TiclopidineThe metabolism of Chlorzoxazone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Chlorzoxazone.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Chlorzoxazone.Experimental
TipranavirThe metabolism of Chlorzoxazone can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Chlorzoxazone can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Chlorzoxazone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Chlorzoxazone.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorzoxazone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Chlorzoxazone.Experimental
TranylcypromineThe metabolism of Chlorzoxazone can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Chlorzoxazone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorzoxazone.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Chlorzoxazone.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Chlorzoxazone.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorzoxazone.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Chlorzoxazone.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorzoxazone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Triprolidine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Chlorzoxazone.Approved, Experimental
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Chlorzoxazone.Approved, Investigational
VemurafenibThe serum concentration of Chlorzoxazone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Chlorzoxazone can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Chlorzoxazone.Experimental
VerapamilThe metabolism of Chlorzoxazone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Chlorzoxazone.Experimental
VoriconazoleThe metabolism of Chlorzoxazone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Chlorzoxazone.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Chlorzoxazone.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Chlorzoxazone.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorzoxazone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Chlorzoxazone can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Chlorzoxazone.Vet Approved
ZolpidemChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Chlorzoxazone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Chlorzoxazone.Approved, Investigational
ZucapsaicinThe metabolism of Chlorzoxazone can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chlorzoxazone.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Marsh, D.F.; US. Patent 2,895,877; July 21, 1959; assigned to McNeil Laboratories, Inc.

General References
  1. Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF: Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6. Epub 2006 Jun 29. [PubMed:16859676]
  2. Park JY, Kim KA, Park PW, Ha JM: Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe. J Clin Pharmacol. 2006 Jan;46(1):109-14. [PubMed:16397290]
  3. Wan J, Ernstgard L, Song BJ, Shoaf SE: Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats. J Pharm Pharmacol. 2006 Jan;58(1):51-61. [PubMed:16393464]
External Links
Human Metabolome Database
HMDB14500
KEGG Drug
D00771
KEGG Compound
C07931
PubChem Compound
2733
PubChem Substance
46507755
ChemSpider
2632
BindingDB
50290811
ChEBI
3655
ChEMBL
CHEMBL1371
Therapeutic Targets Database
DAP000952
PharmGKB
PA448971
IUPHAR
2322
Guide to Pharmacology
GtP Drug Page
HET
CLW
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Chlorzoxazone
ATC Codes
M03BB73 — Chlorzoxazone, combinations with psycholepticsM03BB03 — ChlorzoxazoneM03BB53 — Chlorzoxazone, combinations excl. psycholeptics
PDB Entries
1m8d / 1m9j
MSDS
Download (61.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceDrug Drug Interactions1
1CompletedDiagnosticCytochrome / Pharmacokinetics1
4Active Not RecruitingTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis of Hip1
4CompletedBasic ScienceAlcohol Abuse1
4CompletedTreatmentChlorzoxazone / Postoperative pain1
4RecruitingBasic ScienceType 2 Diabetes Mellitus1
Not AvailableCompletedTreatmentAlcohol Drinking / Attention Deficit Disorder (ADD) / Cessation, Smoking / Depression1

Pharmacoeconomics

Manufacturers
  • Actavis totowa llc
  • Barr laboratories inc
  • Mikart inc
  • Mutual pharmaceutical co inc
  • Ohm laboratories inc
  • Par pharmaceutical inc
  • Pioneer pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
  • Ortho mcneil pharmaceutical inc
  • Ortho mcneil janssen pharmaceuticals inc
  • Ferndale laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOcclusive dressing technique500 mg/1
TabletOral250 mg/1
TabletOral375 mg/1
TabletOral500 mg/1
TabletOral750 mg/1
Prices
Unit descriptionCostUnit
Parafon forte dsc 500 mg caplet2.65USD caplet
Chlorzoxazone 500 mg tablet0.87USD tablet
Chlorzoxazone 250 mg tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)191-191.5Marsh, D.F.; US. Patent 2,895,877; July 21, 1959; assigned to McNeil Laboratories, Inc.
water solubility1000 mg/LNot Available
logP1.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.96 mg/mLALOGPS
logP2.09ALOGPS
logP1.94ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)9.39ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity41.07 m3·mol-1ChemAxon
Polarizability14.94 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.991
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.8733
P-glycoprotein inhibitor INon-inhibitor0.9784
P-glycoprotein inhibitor IINon-inhibitor0.9263
Renal organic cation transporterNon-inhibitor0.9001
CYP450 2C9 substrateNon-substrate0.8243
CYP450 2D6 substrateSubstrate0.6471
CYP450 3A4 substrateNon-substrate0.5372
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9539
CYP450 2D6 inhibitorNon-inhibitor0.9338
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9522
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.7957
CarcinogenicityNon-carcinogens0.9467
BiodegradationNot ready biodegradable0.9655
Rat acute toxicity2.2388 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8675
hERG inhibition (predictor II)Non-inhibitor0.9659
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-02t9-7900000000-bf1beeca5227a276a1a9
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0900000000-5049b81b3f21c5158973
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-0900000000-c7ee77e191a097d4e0ba
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00lr-0900000000-004a71f655e522e841de
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-4900000000-b7b03cbc9d434e2b03f2
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-003i-9100000000-8a0cf328f650c7cd4780
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0900000000-60a947f3a3a65702c43b

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoxazolones. These are organic compounds containing a benzene fused to an oxazole ring (a five-member aliphatic ring with three carbon atoms, one oxygen atom, and one nitrogen atom) bearing a ketone group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxazoles
Sub Class
Benzoxazolones
Direct Parent
Benzoxazolones
Alternative Parents
Benzenoids / Aryl chlorides / Oxazoles / Heteroaromatic compounds / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organochlorides
show 2 more
Substituents
Benzoxazolone / Aryl chloride / Aryl halide / Benzenoid / Azole / Oxazole / Heteroaromatic compound / Azacycle / Oxacycle / Organic oxide
show 9 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
1,3-benzoxazoles, organochlorine compound, heteroaryl hydroxy compound (CHEBI:3655)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Voltage-gated potassium channel activity
Specific Function
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
Gene Name
KCNMA1
Uniprot ID
Q12791
Uniprot Name
Calcium-activated potassium channel subunit alpha-1
Molecular Weight
137558.115 Da
References
  1. Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF: Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6. Epub 2006 Jun 29. [PubMed:16859676]
  2. Alvina K, Khodakhah K: KCa channels as therapeutic targets in episodic ataxia type-2. J Neurosci. 2010 May 26;30(21):7249-57. doi: 10.1523/JNEUROSCI.6341-09.2010. [PubMed:20505091]
  3. Syme CA, Gerlach AC, Singh AK, Devor DC: Pharmacological activation of cloned intermediate- and small-conductance Ca(2+)-activated K(+) channels. Am J Physiol Cell Physiol. 2000 Mar;278(3):C570-81. [PubMed:10712246]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159]
  2. Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. [PubMed:9879636]
  3. Ernstgard L, Warholm M, Johanson G: Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. Br J Clin Pharmacol. 2004 Aug;58(2):190-200. [PubMed:15255802]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Wiercinska P, Squires EJ: Chlorzoxazone metabolism by porcine cytochrome P450 enzymes and the effect of cytochrome b5. Drug Metab Dispos. 2010 May;38(5):857-62. doi: 10.1124/dmd.109.030528. Epub 2010 Feb 17. [PubMed:20164110]
  2. Warrington JS, Court MH, Greenblatt DJ, von Moltke LL: Phenacetin and chlorzoxazone biotransformation in aging male Fischer 344 rats. J Pharm Pharmacol. 2004 Jun;56(6):819-25. [PubMed:15231049]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Yang TJ, Sai Y, Krausz KW, Gonzalez FJ, Gelboin HV: Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics. 1998 Oct;8(5):375-82. [PubMed:9825829]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Shimada T, Tsumura F, Yamazaki H: Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80. [PubMed:10534312]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Gorski JC, Jones DR, Wrighton SA, Hall SD: Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica. 1997 Mar;27(3):243-56. [PubMed:9141232]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Shimada T, Tsumura F, Yamazaki H: Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80. [PubMed:10534312]
  3. Gorski JC, Jones DR, Wrighton SA, Hall SD: Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica. 1997 Mar;27(3):243-56. [PubMed:9141232]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:36